

# A minimum threshold for myelination of pyramidal cells in human and mouse neocortex

M. Pascual-García<sup>1</sup>, M. Unkel<sup>1</sup>, J. A. Slotman<sup>2</sup>, A. Bolleboom<sup>3,4</sup>, B. Bouwen<sup>3,4</sup>, A. B. Houtsmuller<sup>2</sup>, C. Dirven<sup>4</sup>, Z. Gao<sup>3</sup>, S. Hijazi<sup>5</sup>#, S.A. Kushner<sup>1</sup>#

<sup>1</sup> Department of Psychiatry, Erasmus MC, Rotterdam, The Netherlands

<sup>2</sup> Erasmus Optical Imaging Centre, Department of Pathology, Erasmus MC, Rotterdam, The Netherlands

<sup>3</sup> Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands

<sup>4</sup> Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands

<sup>5</sup> Department of Pharmacology, University of Oxford, United Kingdom

# These authors contributed equally.

## Abstract

Neocortical pyramidal neurons are frequently myelinated. Diversity in the topography of axonal myelination in the cerebral cortex has been attributed to a combination of electrophysiological activity, axonal morphology, and neuronal-glial interactions. Previously, we showed that axonal segment length and calibre are critical determinants of fast-spiking interneuron myelination (Stedehouder, J. et al (2019)). However, the factors that determine the myelination of individual axonal segments along neocortical pyramidal neurons remain largely unexplored. Here, we used structured illumination microscopy and cell type-specific manipulations to examine the extent to which axonal morphology determines the topography of axonal myelination in mouse neocortical pyramidal neurons. We found that, unlike what was determined for fast-spiking interneurons, the joint combination of axonal calibre and interbranch distance does not predict axonal myelination in pyramidal neurons, rather it provides a minimum threshold for myelination; pyramidal neurons with an axon calibre and interbranch distance lower than 0.24  $\mu$ m and 19  $\mu$ m, respectively, are almost never myelinated. Moreover, we further confirmed that these findings in mice also extend to human neocortical pyramidal cell myelination, suggesting that this mechanism is evolutionarily conserved. Taken together, our findings suggest that axonal morphology is highly deterministic of the topography and cell-type specificity of neocortical myelination.

## 32 **Introduction**

33 Diverse neuronal types are synaptically connected within the cerebral cortex forming complex  
34 and interactive circuits between different subcortical layers and brain regions. Axonal  
35 myelination is a crucial mammalian neurobiological adaptation that functions as an electrical  
36 insulator, enabling saltatory conduction of action potentials<sup>1</sup>, facilitating reliably timed  
37 neuronal activity<sup>2,3</sup>, and optimizing neuronal energy expenditure<sup>4</sup>. Accordingly, loss or  
38 damage to the myelin sheath or oligodendrocyte integrity has been shown to contribute to a  
39 variety of neuropsychiatric disorders<sup>5</sup>.

40 Myelin composition varies across brain regions. Developmentally, CNS myelination exhibits  
41 protracted maturation throughout childhood, adolescence and early adulthood, with  
42 considerable cell-type heterogeneity, as well as across distinct subcortical layers and brain  
43 areas<sup>6,7</sup>. In particular, the topography of myelination along individual axons of neocortical  
44 pyramidal neurons is known to be highly heterogeneous<sup>8,9,10</sup>. This has raised the question of  
45 how oligodendrocytes determine their targets among the totality of axons. Intrinsic molecular  
46 cues from axons have been suggested to inhibit or attract myelinating oligodendrocytes<sup>11,12</sup>.  
47 Moreover, neuronal activity has been shown to contribute to the development of  
48 oligodendrocytes and therefore the sheathing of axons<sup>13</sup>. However, although neocortical  
49 pyramidal cell axons are a well-characterized target of myelinating oligodendrocytes, the  
50 heterogeneity of their internodal topography remains poorly understood.

51 Axonal diameter is widely known to be an important determinant of myelination. Schwann  
52 cells, the myelinating cells in the peripheral nervous system, almost exclusively ensheathe axons  
53 with a diameter greater than ~1  $\mu\text{m}$ <sup>15-17</sup>. In the CNS, oligodendrocytes restrict their  
54 ensheathment to axons with a diameter greater than ~0.3  $\mu\text{m}$ <sup>10,18,19</sup>. However, many axons  
55 exceeding this minimum threshold remain unmyelinated<sup>19</sup>. This suggests that in the CNS, other  
56 factors influence axonal myelination. Previous studies of local fast-spiking interneurons in the  
57 cerebral cortex demonstrated that axonal morphology, including calibre and interbranch  
58 segment length, is sufficient to predict interneuron myelination with high accuracy<sup>19</sup>. Whether  
59 pyramidal cells adhere to similar or distinct rules governing their myelination has yet to be  
60 determined.

61 Here, we investigated the relationship between pyramidal cell axonal morphology and  
62 myelination in layer II/III of mouse somatosensory and prefrontal cortices. We observed that  
63 unlike fast-spiking interneurons, the joint combination of diameter and axonal segment length  
64 is not predictive of segmental myelination in the somatosensory cortex (S1) but rather imposes  
65 a necessary threshold for myelination, deterring the myelination of axons with a calibre and  
66 length that are lower than the identified respective thresholds. We found that, in the prefrontal  
67 cortex (PFC), pyramidal cells are rarely myelinated at 8-12 weeks of age, likely due to their

68 immature axonal morphology. Lastly, using human *ex vivo* neurosurgically resected tissue, we  
69 confirmed that the morphological thresholds for neocortical pyramidal cell myelination in mice  
70 also extend to human. Taken together, local axonal morphology of pyramidal cells appears to  
71 explain a substantial proportion of the variance underlying segmental myelination and might  
72 function as a causal biophysical constraint for oligodendrocytes to initiate axonal myelination.


## 73 **Results**

### 74 **Myelination of neocortical pyramidal cells in the somatosensory cortex is associated with 75 axonal morphology**

76 To establish the relationship between axonal morphology and myelination of pyramidal cells  
77 in the somatosensory cortex (S1), we performed whole-cell patch-clamp recordings in S1 slices  
78 from wild-type (WT) mice at 8-12 weeks (**Figure 1a, b; Supplementary table 1a**). Biocytin-  
79 labelled neurons were imaged using confocal microscopy and immunostained with myelin  
80 basic protein (MBP) to investigate their myelination profile (**Figure 1c**). 80% (8 out of 10) of the  
81 examined cells were myelinated. Consistent with previous studies<sup>9</sup>, only the primary axon had  
82 myelinated segments (**Figure 1d; Supplementary table 1b**). Axonal diameter and length of  
83 each reconstructed segment were measured using SIM imaging. The axonal shaft diameter,  
84 independent of myelination status, had an average diameter of 0.262  $\mu\text{m}$  (**Figure 1e**).  
85 Importantly, segments that exhibited myelination had a larger calibre compared to those that  
86 were unmyelinated. Moreover, myelinated segments were longer on average than those that  
87 were unmyelinated (**Figure 1f, g**).

88 Using receiver operating characteristic (ROC) analysis, we examined the sufficiency of axonal  
89 calibre and length to predict segmental myelination in S1 pyramidal neurons. As expected,  
90 axonal diameter was a significant predictor of segmental myelination with a critical threshold  
91 at 0.346  $\mu\text{m}$  (AUC = 0.97; sensitivity = 0.85; specificity = 0.85). Axonal length was also  
92 significantly associated with segmental myelination, albeit with a somewhat lower specificity  
93 (threshold, 18.90  $\mu\text{m}$ ; AUC = 0.87; sensitivity = 1; specificity = 0.65). Therefore, we performed  
94 a bivariate ROC analysis as previously described<sup>19</sup>, in order to determine whether the joint  
95 combination of axonal calibre and length might yield better estimates of segmental  
96 myelination along pyramidal cell axons. The combination of both parameters yielded a  
97 significant yet mild improvement in the prediction of segmental myelination (AUC = 0.97;  
98 sensitivity = 1; specificity = 0.88), with thresholds for axonal calibre and length of 0.236  $\mu\text{m}$  and  
99 18.14  $\mu\text{m}$ , respectively (**Figure 1h, i**; axonal calibre:  $p < 0.01$ ; axonal length:  $p < 0.01$ ).  
100 Importantly, the specificity and accuracy of the prediction was still below 90%. This is  
101 demonstrated by the many unmyelinated segments that crossed the identified threshold  
102 (10/24). Given that none of the segments below the threshold were myelinated, this data  
103 suggests that our bivariate model presents a threshold that is necessary for myelination but

104 not critical; pyramidal neurons with a joint combination of axonal calibre and length that are  
 105 below 0.24  $\mu\text{m}$  and 19  $\mu\text{m}$  respectively will not be myelinated.



106


107 **Figure 1. Axonal properties of pyramidal cells in the mouse S1.** **a)** Example of a pyramidal cell in S1  
 108 filled with biocytin. **b)** Electrophysiological example traces of a layer II-III pyramidal cell at hyperpolarising  
 109 (light blue) and depolarising currents (blue and dark blue). **c)** High magnification picture of a myelinated  
 110 segment (biocytin in blue; MBP in green). Arrow heads indicate myelinated segments. **d)** Neurolucida  
 111 reconstruction of a representative S1 pyramidal cell including the myelinated segments in the main axon  
 112 (axon in blue; myelin in green). **e)** Frequency histogram of the axonal segment calibre, fitted with a  
 113 Gaussian curve; mean = 0.28  $\mu\text{m}$   $\pm$  0.008  $\mu\text{m}$  s.e.m.; n = 98 axonal segments from 10 cells. **f)** Comparison  
 114 of the axonal segment length between myelinated and unmyelinated segments (Mann-Whitney: U = 149;  
 115 p-value < 0.0001; unmyelinated segments = 14.71  $\mu\text{m}$ ; myelinated segments = 43.56  $\mu\text{m}$ ; n = 98  
 116 segments). **g)** Calibre of myelinated and unmyelinated segments (t-test: t = 5.851; p-value < 0.0001;  
 117 unmyelinated segments = 0.26  $\mu\text{m}$ ; myelinated segments = 0.39  $\mu\text{m}$ ; n = 98 segments). **h)** Distribution  
 118 of the axonal segment calibre and interbranch distances for myelinated (green) and unmyelinated (black)

119 segments. Dotted lines depict the bivariate thresholds indicated in figure **i**) ROC curves for univariate  
120 (length or calibre) and bivariate analyses.

121 **Prefrontal cortex layer II-III pyramidal cells are seldomly myelinated in mice**

122 Next, we aimed to investigate whether the above observations were similar in a different  
123 neocortical region. Using the same workflow as in S1, we patched and filled pyramidal cells  
124 with biocytin in the prefrontal cortex (PFC) of naïve wild-type mice (**Figure 2a, b**;  
125 **Supplementary table 2**). The targeted cells were immunostained with MBP to study their  
126 myelination profile. 95% (17 out of 18) of the cells showed no myelination, and 1 cell showed  
127 one myelinated segment on the totality of its axon (**Figure 2c-e**). This is consistent with earlier  
128 reports that myelination in the PFC occurs later in development than other neocortical  
129 regions<sup>20</sup>. Does this lack of myelination in PFC pyramidal neurons reflect an immature  
130 morphological profile of their axons compared to S1? To answer this, we performed structural  
131 illumination microscopy (SIM) and measured the diameter of individual axonal segments of the  
132 reconstructed PFC cells. We found that the distribution of axonal calibre was significantly  
133 different in S1 when compared to PFC; only 4.1% of PFC segments had a calibre larger than  
134 0.4  $\mu$ m whereas 12.8% of S1 segments were above 0.4  $\mu$ m (**Figure 2f,g**). It is also interesting to  
135 note that the biggest shift in the curve was above the minimum threshold of 0.24  $\mu$ m (dashed  
136 green line, **Figure 2g**). No significant difference was observed in the distribution of the axonal  
137 segment's length, suggesting that these two variables alone can't explain the difference  
138 reported in the percentage of myelinated pyramidal cells in S1 versus PFC. Unsurprisingly, the  
139 necessary threshold obtained for S1 (axonal calibre below 0.24  $\mu$ m and length below 19  $\mu$ m)  
140 was applicable for PFC pyramidal neurons as none of the segments examined were  
141 myelinated.

142




143

144 **Figure 2. Axonal properties of pyramidal cells in the PFC.** **a)** Pyramidal cell filled with biocytin (blue)  
145 and immunostained with MBP (green) to visualise its myelination. Arrow head indicates main axon. **b)**  
146 Electrophysiological example traces of a layer II-III pyramidal cell at hyperpolarising (light blue) and  
147 depolarising currents (blue (rheobase) and dark blue). **c)** High resolution picture of an unmyelinated  
148 segment of a pyramidal cell in PFC (cell in blue and MBP in green). **d)** Neurolucida reconstruction of the  
149 pyramidal cell in a). **e)** Proportion of myelinated cells in the PFC. **f)** Histogram of the distribution of axonal  
150 segment calibre fitted with a Gaussian curve; mean =  $0.26 \mu\text{m} \pm 0.0073 \mu\text{m}$  s.e.m; n = 98 axonal segments  
151 from 19 cells. **g)** Cumulative frequency distribution of axon calibre of all segments from S1 (green) and  
152 PFC (grey). **h)** Cumulative frequency distribution of axon length of all segments from S1 (green) and PFC  
153 (grey). The dashed line indicates the minimum myelination threshold.

154 **Genetic enlargement of PFC pyramidal cell size increases their likelihood of myelination**

155 Prior studies have demonstrated that increasing cell size can promote myelination of the  
156 individually targeted cells<sup>19,21</sup>. Given that we observed nearly no myelinated segments in PFC

157 pyramidal cells at 8-12 weeks, we wondered whether increasing their size might alter the  
158 minimum threshold and facilitate their myelination. To examine this possibility, we induced a  
159 cell-type specific deletion of the *Tsc1* gene, a negative regulator of the mTOR signalling  
160 pathway and determinant of cell size<sup>22</sup> (**Supplementary figure 1a**). At P28, adeno-associated  
161 virus (AAV9) expressing cre recombinase with an N-terminal GFP tag (GFP-Cre) under the  
162 control of the  $\alpha$ CaMKII promotor was stereotactically injected into the PFC of one hemisphere  
163 of homozygous floxed *TSC1<sup>fl/fl</sup>* mice, while the contralateral PFC was injected with a control virus  
164 that expressed GFP alone (**Figure 3a**). In both hemispheres, all GFP expressing cells had a  
165 pyramidal morphology, consistent with the cell-type selectivity of the  $\alpha$ CaMKII promotor<sup>23</sup>  
166 (**Figure 3b, 4c**). Moreover, cells in the hemisphere expressing GFP-Cre exhibited elevated  
167 pS6, consistent with deletion of the *Tsc1* gene, in contrast to the contralateral hemispheres  
168 expressing GFP alone (**Supplementary figure 1b**). Accordingly, as expected, GFP-Cre  
169 expressing pyramidal cells, but not those expressing GFP alone, exhibited a pronounced  
170 increase in soma area (**Figure 3b, c**).




171  
172 **Figure 3. Tsc1 deletion enlarges pyramidal cells.** **a)** 4-weeks *TSC1<sup>fl/fl</sup>* mice were virally injected with  
173 unilateral CamKII-GFP-cre and contralateral CamKII-GFP viruses in the PFC. One month later mice were  
174 sacrificed and analysis were carried out. **b)** Confocal images of the area of injection at 40x resolution  
175 depicting colocalization of NeuN (red), PS6 (yellow), GFP (green) and Dapi (blue). GFP in GFP-Cre cells is

176 only visible in the nucleus because Cre expression is nuclear, whereas GFP in GFP cells is found along  
177 the whole cytoplasm. Scale bar 20  $\mu\text{m}$ . **c**) Box plot of the area of the soma of NeuN- and GFP- positive  
178 cells (Mann-Whitney:  $U = 5625$ ;  $p$ -value < 0.0001; GFP average:  $117.2 \mu\text{m}^2$ ,  $n = 163$  cells from 4 mice;  
179 GFP-Cre average:  $173.5 \mu\text{m}^2$ ,  $n = 207$  cells from 4 mice).

180 Next, we investigated whether pyramidal cell-specific deletion of TSC1 enhanced their  
181 myelination. Therefore, we patched and filled GFP-labelled cells in the PFC, and stained for  
182 MBP (**Figure 4a-c**). GFP-Cre neurons showed decreased excitability; the action potential (AP)  
183 threshold was increased and the firing frequency was reduced at small depolarising steps,  
184 compared to GFP neurons (**Supplementary figure 2a**). Moreover, along with their increased  
185 size, both the capacitance and axonal calibre of GFP-Cre cells were significantly increased  
186 compared to GFP control cells (**Figure 4d; Supplementary figure 2a, b**). Consistent with the  
187 increased axonal calibre, the proportion of myelinated GFP-Cre cells increased substantially  
188 compared to GFP cells (GFP-Cre, 10 of 16 cells, 62.5%; GFP alone, 5 of 19 cells, 26.3%;  $P <$   
189 0.05, Fisher's Exact Test; **Figure 4e**). Importantly, the cut-off threshold for myelination held true  
190 for both data sets; only 1 segment out of 30 in GFP-Cre and 1 out of 40 in GFP mice with an  
191 axon calibre below 0.24  $\mu\text{m}$  and a length less than 19  $\mu\text{m}$  were myelinated. The increased  
192 number of myelinated segments in the GFP-Cre mice was driven by the increased calibre size  
193 as most of the myelinated segments had an axonal diameter larger than 0.45  $\mu\text{m}$ .

194 To determine whether the increase in the proportion of myelinated GFP-Cre cells also induced  
195 changes in the topography of myelination along individual axons, we performed Neurolucida  
196 reconstructions of filled cells and quantified the number and length of internodes (**Figure 4c**).  
197 We found no differences in the number of myelinated segments, the total amount of myelin  
198 per cell or the average internode length (**Figure 4f-i**). Together, these data show that  
199 enlargement of pyramidal neurons increases the proportion of myelinated axons due to an  
200 increase in their axonal calibre, but without an overall increase in myelination per cell.




201

**Figure 4. Axonal properties of pyramidal cells in the PFC.** **a)** Representative example of filled PFC pyramidal cells. Arrow heads indicate the main axon. Zoom in of colocalization of GFP with biocytin-filled cells. **b)** High magnification confocal image of biocytin-labelled GFP (left) and GFP-Cre (right) pyramidal cells (dark blue) and its myelinated segments (MBP in green). Arrow heads indicate the myelinated segments. Scale bar 10  $\mu$ m. **c)** Example of Neurolucida axonal reconstruction of an unmyelinated GFP pyramidal cell (top) and a myelinated GFP-Cre pyramidal cell (down). **d)** Violin plot showing that axonal calibre is larger in GFP-Cre cells compared to GFP cells (Mann-Whitney:  $U = 4296$ ;  $p$ -value  $< 0.0001$ ; GFP average: 0.25  $\mu$ m,  $n = 104$  segments from 9 cells; GFP-Cre average: 0.30  $\mu$ m,  $n = 120$  segments from 13 cells). **e)** The proportion of myelinated cells is increased in GFP-Cre cells compared to GFP cells (Fisher's exact test:  $p$ -value = 0.044; GFP-Cre: 62.5% (10 out of 16); GFP: 26.3% (5 out of 19)). **f)** Number of myelinated segments is the same in both groups (t-test:  $t = 0.1389$ ;  $p$ -value = 0.89; GFP average: 2.5 myelinated internodes; GFP-Cre average: 2.3 myelinated segments). **g)** Total amount of myelin is the same across groups (t-test:  $t = 0.5245$ ;  $p$ -value = 0.61; GFP average: 88.37  $\mu$ m; GFP-Cre average: 64.01  $\mu$ m). **h)** Average myelin length is similar between groups (t-test:  $t = 0.7572$ ;  $p$ -value = 0.46; GFP average: 32.01  $\mu$ m; GFP-Cre average: 27.35  $\mu$ m). **i)** The average internode length remains the same in both conditions (t-test:  $t = 1.094$ ;  $p$ -value = 0.29; GFP average: 35.35  $\mu$ m; GFP-Cre average: 28.06  $\mu$ m).  $n_{\text{GFP}} = 5$  cells;  $n_{\text{GFP-Cre}} = 10$  cells.

219 **Human neocortical pyramidal neurons exhibit a similar morphological relationship with**  
220 **axonal myelination**

221 As our previous data uncovered a predictive role for axonal morphology in the myelination  
222 of fast-spiking interneurons in mice and in humans, we next wondered if what the minimum  
223 threshold observed in mice pyramidal neurons holds true for human pyramidal neurons. To  
224 that end, we performed whole-cell electrophysiology and biocytin-filling of patched human  
225 pyramidal cells in neurosurgically resected neocortical tissue (9 cells from 5 patients; see  
226 *Methods*). Pyramidal cells were visually targeted by their stereotypical morphology. All  
227 recorded cells exhibited canonical electrophysiological characteristics of pyramidal neurons  
228 such as regular firing frequency, high amplitude and the subthreshold depolarisation (**Figure**  
229 **6a, b; Supplementary table 3a**). *Post hoc* MBP immunofluorescence revealed that 89% of the  
230 cells (8 out of 9) were myelinated with an average internode length of  $49.37 \pm 12.69 \mu\text{m}$ , total  
231 myelin length of  $162.21 \pm 82.3 \mu\text{m}$  and  $2.87 \pm 1.25$  number of internodes (**Figure 6c, d**;  
232 **Supplementary table 3b**).

233 Super-resolution analysis of individual axonal segments yielded a mean axonal shaft diameter  
234 of  $0.289 \pm 0.77 \mu\text{m}$  (**Figure 6e**). Similar to our observations in S1 pyramidal cells in mice, human  
235 neocortical pyramidal cells revealed a strong association between segmental myelination and  
236 the joint combination of axonal diameter and axonal length. Segments that lacked myelination  
237 exhibited shorter length and thinner diameters compared to those that were myelinated  
238 (**Figure 6f, g**). ROC analysis of the univariate models revealed thresholds of  $21.75 \mu\text{m}$  for  
239 segment length (AUC = 0.73; sensitivity = 0.90; specificity = 0.51) and  $0.348 \mu\text{m}$  for axonal  
240 diameter (AUC = 0.82; sensitivity = 0.70; specificity = 0.82, respectively). The bivariate analysis  
241 that included the joint combination of axonal calibre and segment length revealed combined  
242 thresholds of  $18.96 \mu\text{m}$  for segment length and  $0.246 \mu\text{m}$  for axonal calibre (AUC = 0.90;  
243 sensitivity = 0.95; specificity = 0.77). The joint combination of both parameters significantly  
244 improved the ROC model compared to univariate models based on axonal calibre ( $P = 0.027$ )  
245 or segment length ( $P < 0.001$ ) (**Figure 6h, i**). Almost all the myelinated segments (1 out of 21)  
246 were above the necessary threshold for myelination. It is interesting to note that S1 pyramidal  
247 neurons from mice and human pyramidal neurons adhere to a very similar limiting threshold  
248 (calibre  $0.24 \mu\text{m}$  in mice vs  $0.25 \mu\text{m}$  in humans; length  $18.14 \mu\text{m}$  in mice vs  $18.96 \mu\text{m}$  humans),  
249 and show a comparable percentage of myelinated pyramidal cells. Together, these data  
250 indicate that myelination adheres to similar morphological thresholds across different species.



251

252 **Figure 6.** Axonal properties of human pyramidal cells. **a)** Confocal image of a representative human  
253 pyramidal cell filled with biocytin. **b)** Electrophysiological example traces of a human pyramidal cell at  
254 different hyperpolarising (light blue) and depolarising currents (blue (rheobase) and dark blue). **c)** High  
255 resolution image of a myelinated segment (MBP; green) in a human pyramidal neuron (dark blue).  
256 Arrowheads delimit myelin internode. **d)** Neurolucida axonal reconstruction of a representative  
257 pyramidal cell (axon in dark blue; myelin in green). **e)** Frequency histogram of the axonal segment calibre,  
258 fitted with a Gaussian curve; mean =  $0.29 \mu\text{m} \pm 0.008 \mu\text{m}$  s.e.m.;  $n = 144$  axonal segments from 10 cells.  
259 **f)** Axonal segments that were myelinated were significantly longer than those that did not present any  
260 internode ( $t$ -test:  $t = 2.989$ ;  $p$ -value = 0.003; unmyelinated segments:  $25.28 \mu\text{m}$ ; myelinated segments:  
261  $38.88 \mu\text{m}$ ). **g)** Axonal calibre of myelinated segments is larger than those unmyelinated ( $t$ -test:  $t = 4.602$ ;  
262  $p$ -value < 0.001; (unmyelinated segments:  $0.27 \mu\text{m}$ ; myelinated segments:  $0.37 \mu\text{m}$ ). **h)** Distribution of  
263 the axonal segment calibre and interbranch distances for myelinated (green) and unmyelinated (black)

264 segments. Dotted lines depict the critical thresholds of the bivariate analysis. **i**) ROC curves for univariate  
265 (length and calibre) and bivariate analyses.

## 266 **Discussion**

267 Pyramidal cells are the major class of excitatory glutamatergic neurons in the cerebral cortex.  
268 Their function, morphology, excitability and number vary across different layers of the  
269 neocortex. The myelination profile of pyramidal cells is highly diverse and depends on their  
270 electrical activity and connectivity<sup>9</sup>. However, few studies have previously been performed to  
271 investigate the cellular determinants underlying the spatial distribution of neocortical  
272 pyramidal cell internodes. In the present study, we provide new insights regarding the  
273 relationship between axonal morphology and the myelination of individual segments along  
274 pyramidal cell axons. We employed cell-specific techniques to assess the causality of this  
275 relationship by genetically targeting individual pyramidal cells and using high-resolution  
276 methods to measure axonal diameter and length. Our findings reveal a cut-off threshold for  
277 the myelination of pyramidal cell axonal segments lower than 18.5  $\mu$ m and thicker than 0.24  
278  $\mu$ m. These results also provide an explanation as to why only the primary axon is myelinated  
279 in neocortical pyramidal cells, as collateral branches protruding from the main axon of  
280 pyramidal neurons have a notably thinner diameter, which is typically subthreshold for  
281 myelination of these segments. Notably, the lack of myelination along branches of pyramidal  
282 cells is in marked contrast to collateral branches of fast-spiking interneurons, which are  
283 frequently myelinated in both mouse and human neocortex<sup>19,24</sup>.

### 284 *Differential myelination profile across brain regions*

285 Internodal topography varies by neuronal type, cortical layer and brain region<sup>25</sup>. Cortical layers  
286 V-VI, for instance, are densely myelinated in comparison to more superficial layers<sup>9</sup>. Consistent  
287 with earlier studies, we found that pyramidal cells in layer II-III of S1 were frequently myelinated.  
288 Myelinated segments of these cells were on average longer and thicker than those that were  
289 unmyelinated (**Figure 1**).

290 In contrast to the findings in S1, we found that pyramidal cells in layer II-III of the PFC were  
291 rarely myelinated in naïve mice at 8-12 weeks of age. Interestingly, myelin sheaths were  
292 detectable on other neuronal types, such as local interneurons in the same area<sup>24</sup>, indicating  
293 that the lack of myelin on pyramidal neurons is not due to an absence of myelinating  
294 oligodendrocytes in this region. Why are pyramidal neurons not myelinated in the PFC at this  
295 age? One explanation could be that these cells are not yet fully mature. The PFC is critically  
296 involved in complex cognitive and executive function<sup>27</sup>, and developmentally one of the last  
297 regions to mature, undergoing continual changes through adolescence until early  
298 adulthood<sup>28</sup>. It is well-established that the PFC in humans is one of the last regions to become  
299 fully myelinated<sup>29,30</sup>. Moreover, cortical myelination in mice exhibits a similar developmental  
300 trajectory, peaking at one year of age<sup>31,32</sup>. Electrical cues acquire critical relevance during

301 development, and activity-dependent myelination and crucial for remodelling the brain's  
302 networks<sup>14</sup>. Another likely explanation is that, as the mice used in the study were naïve young  
303 adults, very little experience-dependent myelination had occurred in the PFC at this stage. It is  
304 interesting to note that, in mice injected with the control GFP virus, 5 out of 19 pyramidal cells  
305 showed myelination, as opposed to what was observed in naïve untreated mice (1 out of 18),  
306 suggesting a role for intracranial injections in the myelination of axons. In fact, mice that  
307 received sham intracranial injection (no virus injected) also showed some myelinated segments  
308 in PFC pyramidal neurons (data not shown).

309 *Cellular morphology is linked to excitability and myelination*

310 Our previous work demonstrated that enlargement of neocortical fast-spiking interneurons by  
311 deletion of *Tsc1* increased the number and length of internodes in these cells<sup>19</sup>. Likewise,  
312 manipulation of pyramidal cells in *Tsc1<sup>ff</sup>* mice increased cell size, including axonal calibre. The  
313 proportion of GFP-Cre pyramidal cells that were myelinated increased substantially in PFC.  
314 These data suggest that *de novo* myelination may be induced in unmyelinated cells by altering  
315 their axonal morphology but does not affect the number of pre-existing internodes. Notably,  
316 the required distance between sodium clusters in paranodal regions is on average ~32 µm,  
317 which might explain why the minimum segmental length is at least 17 µm<sup>33</sup> for  
318 oligodendrocytes to ensheathe axons.

319 Neuronal excitability is another factor to take into consideration as a potential determinant of  
320 myelination profiles. Adaptations of axonal diameter have been observed in response to  
321 neuronal stimulation<sup>34</sup>. Neuronal activity enhances myelin formation and regulates the  
322 complexity of axonal arborization as well as the thickness and number of myelinated segments  
323 in both excitatory and inhibitory neurons<sup>14,35,36</sup>. Previous studies have observed a relationship  
324 between pyramidal cells' firing frequency and larger axonal diameter, which serves to reduce  
325 their energetic consumption by enhancing their axonal myelination<sup>26,37</sup>. Notably, we observed  
326 that enlarged GFP-Cre pyramidal cells in the PFC exhibited reduced excitability, with a higher  
327 AP threshold and reduced peak and firing properties compared to their control littermates  
328 (**Supplementary figure 2a**). Together, we find that, at the individual cell level, the relationship  
329 between axonal myelination and experimental manipulation of pyramidal cell size more closely  
330 follows changes in morphology rather than excitability, indicating that myelination is not only  
331 driven by activity but also by morphological plasticity.

332 *Biophysical cues for oligodendrocyte attraction*

333 Extrinsic and intrinsic cues guide oligodendrocyte precursor cells (OPCs) to mature into  
334 myelinating oligodendrocytes and ensheathe axons<sup>38</sup>. Beyond fibre diameter, axon curvature  
335 has also been suggested to play an important permissive role in myelination<sup>39</sup>. Bechler, et al.  
336 demonstrated that oligodendrocytes increase the sheath length in larger fibres<sup>40</sup>. Our results

337 indicate that axonal length also creates a physical constraint for myelination, given that  
338 segments shorter than 18  $\mu\text{m}$  are mostly unmyelinated. Furthermore, axonal branch points are  
339 consistently unmyelinated, which might suggest that the angle formed by the emerging  
340 daughter branches biophysically restricts oligodendrocyte ensheathment. Consistent with this  
341 finding, branch points of myelinated axons are also common locations for nodes of Ranvier  
342 and therefore critical for signal integration along the axon<sup>41,42</sup>.

343 *Pyramidal cell myelination is stable across species*

344 Pyramidal cells in the human neocortex are extensively myelinated<sup>9</sup>. Single-cell axonal  
345 reconstruction of pyramidal cells in different brain areas, including frontal and temporal  
346 cortices, showed that almost 90% of human pyramidal cells were myelinated. This increased  
347 myelination ratio in humans when compared to mice could be due to a mere species difference  
348 or another more likely explanation is that it is the result of a difference in learning-induced  
349 myelination in humans, as all the mice used in this experiment were naïve young adults  
350 whereas the mean age of the patients in this study was 55 years old. Interestingly, bivariate  
351 analysis revealed human myelination thresholds of 18.96  $\mu\text{m}$  for segment length and 0.25  $\mu\text{m}$   
352 for axonal diameter, which are very similar to what we found in S1 cells from mice (18.14  $\mu\text{m}$   
353 and 0.24  $\mu\text{m}$ , respectively). Such similarities suggest that oligodendrocytes have intrinsic  
354 mechanisms for myelination that are highly preserved across species and guarantee the  
355 correct functioning of the network. Likewise, fast-spiking interneurons also exhibit highly  
356 similar morphological thresholds<sup>19</sup>, suggesting that oligodendrocyte ensheathment potential  
357 might be independent of neuronal cell type and strongly determined by biophysical  
358 constraints.

359 In conclusion, pyramidal cell axonal morphology is a major determinant of myelin topography.  
360 Moreover, the predictive thresholds for axonal calibre and length are similar across multiple  
361 regions in mouse and human neocortex, suggesting the possibility of an evolutionarily  
362 conserved biophysical mechanism governing CNS axonal myelination.

363 **Materials and Methods**

364 **Mice**

365 All experiments were conducted under the approval of the Dutch Ethical Committee and in  
366 accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines.

367 For this study, two different mouse lines, obtained from Jackson Laboratory, were utilised:  
368 C57BL/6J (referred as WT; strain #000664) and *Tsc1*<sup>tm1Dik</sup>/J (referred as *Tsc1*<sup>fl/fl</sup>; strain #005680).  
369 All lines were backcrossed for more than 10 generations in C57BL/6J. Inducible TSC1  
370 knockout mice were generated by crossing conditional biallelic floxed *Tsc1* mutant  
371 heterozygous mice (*Tsc1*<sup>fl/fl</sup>) in C57BL/6J background. Mutant lines were backcrossed to obtain

372 homozygous *Tsc<sup>ff</sup>* mice. All mutant lines were viable and healthy. No behavioural  
373 abnormalities and no spontaneous seizures were ever observed.

374 Mice between 8 and 12 weeks old were used in these experiments. All groups consisted of  
375 mice from both sexes. WT animals were group-housed whereas those animals that underwent  
376 surgical procedure were single-housed after the viral injection. All mice were maintained on a  
377 regular 12 h light/dark cycle at 22 °C (±2 °C) with access to food and water *ad libitum*.

378 **Human**

379 Peri-tumoral neocortical tissue was obtained from 5 patients undergoing tumour resection  
380 surgery at the Department of Neurosurgery (Erasmus University Medical Center, Rotterdam,  
381 The Netherlands). A written informed consent was signed by all patients accordingly to the  
382 Helsinki Declaration.

- 383 – Patient 1 was a 52-year-old-male with a tumour in the right temporal lobe secondary to a  
384 melanoma. There were no episodes of epilepsy or mental illness associated. The patient  
385 did not receive antiepileptic medication.
- 386 – Patient 2 was a 62-year-old male with a glioblastoma on the right temporal lobe. The  
387 patient presented epilepsy secondary to the tumour.
- 388 – Patient 3 was a 32-year-old male with and oligodendrogloma on the right fronto-temporal  
389 lobe. The patient received treatment for epileptic seizures.
- 390 – Patient 4 was a 60-year-old male who underwent surgery due to a tumour in the right  
391 frontal lobe derived from a lung carcinoma. There was no past psychiatric history or  
392 presence of epilepsy or seizures.
- 393 – Patient 5. Was a 69-year-old female who showed signs of glioblastoma in the right  
394 temporo-parietal lobe. There was no history of mental illness or presence of epilepsy.

395 **Viral labelling**

396 Homozygous TSC::cre mice were used for cell-type specific labelling using a cre-dependent  
397 adeno-associated virus (AAV) expression. Mice were injected at 4 weeks of age with  
398 pENN-AAV.CamKII.HI.GFP-Cre.WPRE.SV40 (Addgene viral prep # 105551-AAV9) in the right  
399 hemisphere to silence *Tsc1* gene and pENN-AAV9.CamKII0.4.eGFP.WPRE.rBG (Addgene viral  
400 prep # 105541-AAV9) in the left hemisphere for control conditions. Viruses were diluted to 1/6  
401 and 1/10 respectively to obtain a titer of 1×10<sup>12</sup> vg/mL, in phosphate-buffered saline (PBS) to  
402 obtained sparse and region-focused labelling.

403 Mice were anaesthetised using 5% isofluorante (O<sub>2</sub> flow of 0.5 L/min) and maintained with 2%  
404 isofluorante and 0.55% oxygen during surgery. Mice were placed in a stereotaxic frame using  
405 a mouth bar (Soelting) for head fixation, and their body temperatures was maintained at 37°C  
406 during the whole procedure. Animals were subcutaneously injected with Temgesic

407 (buprenorphine 0.5 mg/kg) and Xylocaine (100 mg/mL, AstraZeneca) was sprayed locally on  
408 the skull to reduce pain and inflammation. A scalp incision was made to access the skull and a  
409 craniotomy was performed at the following sites of injection (in mm): mPFC: +1.75  
410 bregma,  $\pm 0.35$  lateral, -1.9 dorsoventral. Viral injection (100 nL per injection site) was  
411 performed using a borosilicate glass micropipette controlled by a syringe pump (infusion  
412 speed 0.05  $\mu$ L/min). At the end of the injection, the micropipette was sustained in place for 5  
413 minutes before withdrawal. The incision was closed with skin-glue (Derma+flex). After surgery,  
414 mice recovered for 4-6 weeks before electrophysiological or immunohistochemical analysis  
415 were executed.

416 **Electrophysiology**

417 **Mice**

418 Mice were anaesthetised using 5% isoflurane. After decapitation, brains were removed in ice-  
419 cold partial sucrose-based solution containing (in mM): sucrose 70, NaCl 70, NaHCO<sub>3</sub> 25, KCl  
420 2.5, NaH<sub>2</sub>PO<sub>4</sub> 1.25, CaCl<sub>2</sub> 1, MgSO<sub>4</sub> 5, sodium ascorbate 1, sodium pyruvate 3 and D(+)-  
421 glucose 25 (carboxygenated with 5% CO<sub>2</sub>/95% O<sub>2</sub>). Coronal slices from the prefrontal and  
422 somatosensory cortex (300  $\mu$ m thick) were obtained with a vibrating slicer (Microm HM 650V,  
423 Thermo Scientific) and incubated for 45 min at 34 °C in holding artificial cerebro-spinal fluid  
424 (ACSF) containing (in mM): 127 NaCl, 25 NaHCO<sub>3</sub>, 25 D(+)-glucose, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 1.5  
425 MgSO<sub>4</sub>, 1.6 CaCl<sub>2</sub>, 3 sodium pyruvate, 1 sodium ascorbate and 1 MgCl<sub>2</sub> (carboxygenated with  
426 5% CO<sub>2</sub>/95% O<sub>2</sub>). Next, the slices recovered at room temperature for another 15 min.

427 Slices were then transferred into the recording chamber where they were continuously  
428 perfused with recording ACSF (in mM): 127 NaCl, 25 NaHCO<sub>3</sub>, 25 D-glucose, 2.5 KCl, 1.25  
429 NaH<sub>2</sub>PO<sub>4</sub>, 1.5 MgSO<sub>4</sub> and 1.6 CaCl<sub>2</sub>. Cells were visualized using an upright microscope  
430 (BX51WI, Olympus Nederland) equipped with oblique illumination optics (WI-OBCD;  
431 numerical aperture 0.8) and a 40x water-immersion objective. Images were collected by a CCD  
432 camera (CoolSMAP EZ, Photometrics) regulated by Prairie View Imaging software (Bruker). In  
433 WT mice, layer II-III pyramidal cells in the frontal and somatosensory cortex were  
434 distinguishable by their morphological traits. In TSC<sup>hom</sup> mice, transfected neurons were  
435 visualized by eGFP expression using a GFP filter (Semrock, Rochester, NY, USA).

436 Electrophysiological recordings were acquired using HEKA EPC10 quattro amplifiers and  
437 Patchmaster software (10 Hz sampling rate) at 33°C. Patch pipettes were pulled from  
438 borosilicate glass (Warner instruments) with an open tip of 3.5-5 M $\Omega$  of resistance and  
439 filled with intracellular solution containing (in mM) 125 K-gluconate, 10 NaCl, 2 Mg-ATP, 0.2  
440 EGTA, 0.3 Na-GTP, 10 HEPES and 10 K2-phosphocreatine, pH 7.4, adjusted with KOH (280  
441 mOsmol/kg), with 5 mg/mL biocytin to fill the cells. Series resistance was kept under 20 M $\Omega$

442 with correct bridge balance and capacitance fully compensated; cells that exceeded this value  
443 were not included in the study. Cells were filled with biocytin for at least 20 min.

444 Data analysis was performed offline using with Axograph X Office software (v1.7.0, Axograph  
445 Scientific). Physiological characteristics were determined from voltage responses to current  
446 injection pulses of 500 ms duration in 100 pA intervals ranging from -100 to +600. Action  
447 potential (AP) characteristics were obtained by the first elicited AP in the voltage response; AP  
448 peak was defined as the maximum peak of the AP; AP half-width was measured as the half of  
449 the peak amplitude. AP threshold was determined as the first inflection point where the rising  
450 membrane potential exceeded 50mV/ms slope. AP rise time was quantified as duration from  
451 10% to 90% of the peak amplitude. AP decay time was measured as the duration from 100%  
452 to 50% of the peak. The afterhyperpolarisation (AHP) amplitude was measured as the  
453 hyperpolarizing peak from the initiation of the refractory period until the recovery state. AP  
454 frequency was estimated by the inverse of the difference between two consecutive AP in each  
455 current step. Likewise, passive membrane properties such as input resistance or conductance  
456 were calculated by the slope of the linear regression through the voltage-current curve. EPSC  
457 were recorded at -70 mV holding potential during 5 min. Synaptic events were analysed using  
458 Mini Analysis Program (Synaptosoft, Decatur, GA).

459 *Human*

460 Ex vivo human recordings of acutely resected cortex slices were obtained by overlying tissue  
461 that was removed in order to gain access to the tumour. After resection, the tissue block was  
462 transferred into carboxygenated (95% O<sub>2</sub>/5% CO<sub>2</sub>) ice-cold solution and sliced into 300 µm  
463 thick slices for electrophysiology. For the electrophysiological recordings, only slices where  
464 there was no infiltrating tumour found were utilized. Whole-cell recordings and data analysis  
465 were performed and analysed identically as the mouse tissue, except for current injection  
466 pulses that range from -100 to +600 in 50 pA steps.

467 **Immunohistochemistry**

468 *Mice slices*

469 Mice were anaesthetized intraperitoneally with pentobarbital sodium. Midline skin incision  
470 was made at the thoracic outlet followed by opening of the abdomen and a cut in the  
471 diaphragm and the costal cartilage for cardiac perfusion. The needle was placed into the apex  
472 of the left ventricle and animal was perfused with 4 % formaldehyde (PFA). Brains were  
473 dissected and fixed in 4% PFA for 2 h at room temperature. Next, brains were transferred into  
474 10% sucrose phosphate buffer (0.1 M PB) and stored overnight at 4°C. For better handling and  
475 slicing of the brains, they were embedded in 12% gelatin-10% sucrose blocks and left during  
476 1.5 h at room temperature in 10% paraformaldehyde-30% sucrose solution (PB 0.1 M) and later  
477 incubated overnight in 30% sucrose solution at 4°C.

478 Coronal sections (40  $\mu$ m thick) were sliced using a freezing microtome (Leica, Wetzlar,  
479 Germany; SM 2000R) and stored in 0.1 M PB. Sections were blocked with 0.5% Triton X-100%  
480 (MerkMillipore) and 10% normal horse serum (NHS; Invitrogen, Bleiswijk, The Netherlands) for  
481 1 h at room temperature, and incubated over 72 h at 4°C with mouse anti-NeuN (1:300,  
482 Millipore, MAB377), rabbit anti-pS6<sup>S235/236</sup> (1:300, Cell Signaling Technologies, 2211S) in PBS  
483 buffer containing 0.4% Triton X-100 and 2% NHS. NeuN was visualized using anti-mouse  
484 Alexa647 secondary antibody (1:300, Invitrogen); pS6 was incubated in secondary antibody  
485 anti-rabbit Cy3 (1:300, Invitrogen). Secondary antibodies were incubated at room temperature  
486 for 2 h in PBS buffer containing 0.4% Triton X-100 and 2% NHS. Next, sections were washed  
487 with PBS and coverslipped in Vectashield H1000 fluorescent mounting medium (Vector Labs,  
488 Peterborough, UK).

489 *Mice biotin-filled cells*

490 Layer II-III pyramidal neurons were filled with 5mg/mL biocytin during whole-cell recordings  
491 and then fixed with 4% (PFA) overnight and stored in PBS at 4°C. Slices were rinsed with PBS  
492 and then stained with streptavidin-Cy3 secondary antibody (1:300; Invitrogen), 0.4% Triton X-  
493 100 and 2% NHS in PBS during 3 h. Slices were mounted on slides and coverslipped with 150  
494  $\mu$ l Mowiol (Sigma). After imaging with confocal at 63x, cells were unsealed and rinsed with PBS.  
495 To prevent thinning and dehydration, the slices were left in 30% sucrose overnight before  
496 resectioning. Using a freezing microtome, sections were recut into 40  $\mu$ m slices and stored at  
497 0.1 M PB. Resectioned slices were incubated using primary mouse anti-MBP (1:300) and  
498 secondary anti-mouse Alexa-647 (1:300) for eGFP cells and anti-mouse Alexa-488 (1:300) for  
499 WT mice.

500 *Human*

501 Human pyramidal cells were filled with 5mg/mL biocytin and fixed in 4% PFA overnight. Slices  
502 were washed with PBS and stained with streptavidin-Cy3 secondary antibody (1:300) in a PBS-  
503 based solution containing 0.4% Triton X-100 and 5% bovine serum albumin (BSA; Sigma-  
504 Aldrich, The Netherlands) during 3 h at room temperature. Slices were mounted and  
505 coverslipped. Slices were recut in 40  $\mu$ m slices and then blocked in PBS containing 0.4% Triton  
506 X-100 and 5% BSA and posteriorly stained using mouse anti-MBP (1:300) in PBS, 0.4% Triton  
507 X-100 and 5% BSA during 72 h at 4°C. Secondary antibodies Alexa-488 anti-mouse and  
508 streptavidin-Cy3 were diluted in PBS, 0.4% Triton X-100 and 5% BSA during 3 h at room  
509 temperature. Next, slices were coverslipped and sealed for imaging.

510 **Confocal imaging and reconstruction**

511 Images were taken using a Zeiss LSM 700 microscope (Carl Zeiss) equipped with Plan-  
512 Apochromat 10x/0.45 NA, 40x/1.3 NA (oil immersion) and 63x/1.4 NA (oil immersion)

513 objectives. DAPI, Alexa488, Cy3 and Alexa647-secondary fluorophores were imaged using  
514 excitation wavelengths of 405 nm, 488 nm, 555 nm, and 639 nm, respectively.

515 In WT and human cells, a 10x magnification picture of the cell was taken to know exact distance  
516 from soma to pia, and a whole-cell overview image was acquired using 63x magnification  
517 objective and 555 nm wavelength. Pinhole was kept at 0.2% and gain was set at 750-800 units  
518 to adjust the signal to noise ratio. Biocytin-filled cells were imaged with tiled z-stack images  
519 (512 × 512 pixels) with a step size of 1  $\mu$ m. Resectioned slices of such cells were obtained at  
520 40x magnification using 488 and 555 nm wavelength filters.

521 For TSC<sup>ff</sup> eGFP<sup>+</sup> cells a similar approach was used. A 10x magnification picture was taken to  
522 know location of the cell. To classify the cells in TSC1-specific deletion or control eGFP, a 63x  
523 magnification picture with z-stack (1  $\mu$ m step size) and filters 555 nm and 488 nm was taken.  
524 Axonal examination of virally-labelled cells was obtained by 63x magnification tiled z-stack  
525 images (512 × 512 pixels) with a step size of 1  $\mu$ m using 555 nm wavelength. MBP staining  
526 pictures were acquired using 40x magnification (1024 × 1024 pixels) and excitation  
527 wavelengths of 647 and 555 nm. The same settings were maintained across all pictures to  
528 ensure fluorescence was equally measured.

529 Overview images were then transferred into Neurolucida 360 software (v2.8; MBF Bioscience)  
530 and the axon was reconstructed using the interactive tracing with the Directional Kernels  
531 method. Reconstruction of the axon and myelinated segments were analysed with Neurolucida  
532 Explorer (MBF Bioscience). Distance to the pia and internodes were quantified and observed  
533 using ImageJ (ImageJ 5.12h). Axons were accepted as myelinated when they presented at  
534 least one MBP-positive internode and unmyelinated when no MBP-positive internode could be  
535 identified up to at least 10<sup>th</sup> branch order. The distance to the first branch point was calculated  
536 as the length of the axon from the soma to the first branching axon segment. The distance to  
537 the first myelinated segment was determined as the distance along the axon from the soma to  
538 the initial point of the MBP segment.

539 For quantification of pyramidal-specific deletion of *Tsc1* as well as cell size analyses, one-tiled  
540 z-stack confocal picture was taken with 40x magnification. Stacks were randomly sampled  
541 across layer II-III of the targeted region. Three stacks were quantified per mouse and  
542 hemisphere. Only cells were pS6<sup>S235/236</sup> was overlapping eGFP in the soma were used. Total  
543 immunofluorescent was determined pS6<sup>S235/236</sup> as corrected total cell fluorescence (CTCF), with  
544 the following equation CTCF = integrated density - (area of selected cell x mean fluorescence  
545 of background readings). Randomly selected cells were manually outlined, and area and  
546 integrated density were obtained using ImageJ. To assess the exact area of the cell, NeuN  
547 marker was used in ImageJ to outline the cell and measure its area. No spatial corrections were  
548 made for tissue shrinkage.

549 **Structured illumination microscopy (SIM)**

550 Structured illumination imaging was performed using a Zeiss Elyra PS1 system (Carl Zeiss). 3D-  
551 SIM data was acquired using a 63x/1.4 NA oil immersion objective. A 561 nm 100 mW diode  
552 laser together with a BP 570-650 + LP 750 filter was used to excite the fluorophores. Five  
553 phases and five rotations modulated the grating that was present in the light path during 3D-  
554 SIM acquisition. Serial z-stacks of 110 nm were recorded on an Andor iXon DU 885, 1002 ×  
555 1004 EMCCD camera. Raw data was reconstructed using Zen 2012 software (Zeiss) and  
556 posteriorly analysed in Fiji image analysis software.

557 In order to avoid overexposure from the soma, the first picture was taken starting from the  
558 second branch order axonal segment and continuing along this one. Axonal segments were  
559 imaged from branch point to the subsequent branch point. Bandwidth, offset and exposure  
560 time were regulated manually per segment to prevent oversaturation of the picture.  
561 Reconstructed pictures were loaded into Fiji and analysed using a custom-made script as  
562 previously described by Stedehouder, J. et al<sup>19</sup>.

563 **Statistical analysis**


564 All statistical analysis were operated using GraphPad 8.01. Data was firstly analysed for  
565 normality using Kolmogorov-Smirnov test. No outlier was identified or removed. Data sets  
566 following normal distribution were analysed using unpaired two-tailed *t*-test. Data sets without  
567 a normal distribution were analysed using Mann Whitney test.

568 A self-custom-made algorithm for R was created to calculate the receiver operating  
569 characteristic (ROC) curve, the area under the curve (AUC), the thresholds from the pure length  
570 and diameter univariate models and for the bivariate model. The optimum thresholds were  
571 determined as the maximum point of the Youden's J statistic, calculated as the sum of the  
572 sensitivity and specificity minus 1. The AUC were estimated as the integral of the ROC curves  
573 for the univariate and bivariate models.

574 **Competing interests**

575 The authors declare no conflict of interests.


576 **Supplementary data**



578 **Supplementary figure 1. TSC1 deletion activates the mTOR pathway. a)** mTOR signalling pathway. 579 Green arrows indicate activation and red lines indicate inhibition. When TSC1 is knocked-out the TSC 580 complex cannot be formed and RHEB binds a GTP molecule. In this manner, mTOR becomes active 581 leading to the phosphorylation of ribosomal protein S6 that enables the transduction of growth and 582 proliferation genes. **b)** Box plot of the area of the soma of PS6- and GFP- positive cells (t-test:  $t = 2.68$ ;  $p$ - 583 value = 0.036; GFP average: 17161 AU,  $n = 163$  cells from 4 mice; GFP-Cre average: 34247 AU,  $n = 207$  584 cells from 4 mice). **c)** Drawing of the viral injections in the S1 of TSC<sup>ff</sup> mice.


585

586



587

588 **Supplementary figure 2a. Electrophysiological properties of Cre lines in PFC. a)** Capacitance of GFP-  
 589 Cre cells was increased (t-test: 5.47; p-value < 0.0001; GFP average: 66.68 pF; GFP-Cre average: 123.8  
 590 pF). **b)** AP threshold was reduced (t-test: t = 2.24; p-value = 0.029; GFP average: -39.09 mV; GFP-Cre  
 591 average: -36.17 mV). **c)** No variations in the RMP (t-test: t = 0.07; p-value = 0.94; GFP average: -70.02 mV;  
 592 GFP-Cre average: -70.15 mV). **d)** Input resistance was unchanged (t-test: t = 0.71; p-value = 0.48; GFP  
 593 average: 141.8 MΩ; GFP-Cre average: 129.9 MΩ). **e)** Amplitude was not changed (t-test: t = 0.99; p-value  
 594 = 0.33; GFP average: 35.3 mV; GFP-Cre average: 37.04 pA). **f)** Peak was reduced in GFP-Cre compared  
 595 to their control littermates (t-test: t = 4.034; p-value = 0.0002; GFP average: 96.91 mV; GFP-Cre average:  
 596 90.83 mV). **g)** Half-width was similar between groups (t-test: t = 0.422; p-value = 0.67; GFP average: 0.90  
 597 ms; GFP-Cre average: 0.92 ms). **h)** There was a trend towards higher rheobase (t-test: t = 1.86; p-value =  
 598 0.068; GFP average: 138.6 pA; GFP-Cre average: 182.4 pA). **i)** Rise time was increased (Mann-Whitney:  
 599 U = 200; p-value = 0.058; GFP average: 0.18 ms; GFP-Cre average: 0.23 ms). **j)** Decay time was reduced  
 600 (Mann-Whitney: U = 177; p-value = 0.018; GFP average: 0.71 ms; GFP-Cre average: 0.61 ms). **k)** Firing  
 601 frequency in response to hyperpolarising and depolarising current steps.



602

603 **Supplementary figure 2b. Axonal thresholds of Cre lines in PFC. a)** Distribution of the axonal segment  
604 calibre and interbranch distances for myelinated (green) and unmyelinated (black) segments in GFP-Cre  
605 cells. Dotted lines depict the critical thresholds of the bivariate analysis. **b)** ROC curves for univariate  
606 length (length threshold = 47.55; AUC = 0.63; sensitivity = 0.44; specificity = 0.82), diameter (diameter  
607 threshold = 0.45; AUC = 0.73; sensitivity = 0.67; specificity = 0.86) and bivariate (joint threshold: length  
608 = 10.242, diameter = 0.45; AUC = 0.80; sensitivity = 0.67; specificity = 0.90) analyses of GFP-Cre axonal  
609 segments. **c)** Distribution of the axonal segment calibre and interbranch distances for myelinated (green)  
610 and unmyelinated (black) segments in GFP cells. Dotted lines depict the critical thresholds of the bivariate  
611 analysis. **d)** ROC curves for univariate length (length threshold = 37.21; AUC = 0.84; sensitivity = 1;  
612 specificity = 0.84), diameter (diameter threshold = 0.31; AUC = 0.86; sensitivity = 1; specificity = 0.76)  
613 and bivariate (joint threshold: length = 37.25, diameter = 0.30; AUC = 0.99; sensitivity = 1; specificity =  
614 0.97) analyses of GFP axonal segments.

615

	MEAN	SEM
Capacitance (pF)	62,19	8,32
RMP (mV)	-72,63	1,46
Rinput (MΩ)	202,78	22,04
AP threshold (mV)	-37,93	0,71
AP amplitude (mV)	32	1,84
AP peak (pA)	92,31	2,01
AP half-width (ms)	0,99	0,08
AP rise time (ms)	0,20	0,02
AP decay time (ms)	0,76	0,07
AP threshold (at 300 pA) (Hz)	29,77	2,29
Rheobase (pA)	123,68	17,67

624 **Supplementary table 1. Electrophysiological properties of PFC layer II-III pyramidal cells in WT**  
625 **mice at 8-12 weeks of age.**

a

	MEAN	SEM
Capacitance (pF)	79	16,12
RMP (mV)	-74,09	1,86
Rinput (MΩ)	115,23	19,08
AP threshold (mV)	-32,8	2,43
AP amplitude (mV)	32,92	1,91
AP peak (pA)	89,86	2,98
AP half-width (ms)	1,12	0,13
AP rise time (ms)	0,23	0,03
AP decay time (ms)	0,8	0,13
AP threshold (at 300 pA) (Hz)	22,58	4,49
Rheobase (pA)	244	42,27

b

	MEAN	SEM
Myelinated	80%	
Myelin in the first segment	50%	
Number of internodes	3,29	0,64
Internode length (μm)	25,52	2,64
Average internode length (μm)	22,96	3,45
Total amount of myelin (μm)	83,85	23,65
Distance to first internode (μm)	54,65	16,18
Distance to first branch point (μm)	75,27	4,14
Distance to pia (μm)	276,56	27,25

626

627 **Supplementary table 2. Electrophysiological properties and myelin profile of S1 layer II-III**  
628 **pyramidal cells in mice. a)** Intrinsic properties of S1 pyramidal cells. **b)** Myelin characteristics of S1  
629 pyramidal cells.

630

a

	MEAN	SEM
Capacitance (pF)	78,99	19,91
RMP (mV)	-68,53	2,11
Rinput (MΩ)	189,1	34,67
AP threshold (mV)	-40,79	3,25
AP amplitude (mV)	41,38	2,32
AP peak (pA)	93,99	3,14
AP half-width (ms)	0,96	0,03
AP rise time (ms)	0,24	0,01
AP decay time (ms)	0,67	0,10
AP threshold (at 300 pA) (Hz)	33,03	3,02
Rheobase (pA)	95	19,91

b

	MEAN	SEM
Myelinated	89%	
Myelin in the first segment	38%	
Number of internodes	2,87	1,25
Internode length (μm)	49,37	12,67
Average internode length (μm)	41,31	17,68
Total amount of myelin (μm)	162,21	82,3
Distance to first internode (μm)	149,68	27,14
Distance to first branch point (μm)	137,36	62,73
Distance to pia (μm)	833,37	251,9

631

632 **Supplementary table 3. Electrophysiological and myelination properties of human pyramidal cells.**

633 **a)** Intrinsic properties of human pyramidal cells. **b)** Myelin characteristics of the cells that were myelinated.

634 Correlation between electrophysiology and myelination pattern could not be done because of the low n  
635 of unmyelinated cells.

636

637

## 638 References

- 639 1. Nave, K.-A. & Werner, H. B. Myelination of the nervous system: mechanisms and functions. *Annu. Rev. Cell*  
640 *Dev. Biol.* **30**, 503-533 (2014).
- 641 2. Salami, M., Itami, C., Tsumoto, T. & Kimura, F. *Change of conduction velocity by regional myelination yields*  
642 *constant latency irrespective of distance between thalamus and cortex. PNAS May* **13**, (2003).
- 643 3. Ford, M. C. *et al.* Tuning of Ranvier node and internode properties in myelinated axons to adjust action  
644 potential timing. *Nat. Commun.* **6**, 8073 (2015).
- 645 4. Wang, S. S. H. *et al.* Functional Trade-Offs in White Matter Axonal Scaling. *J. Neurosci.* **28**, 4047-4056 (2008).
- 646 5. Snaidero, N. *et al.* Myelin membrane wrapping of CNS axons by PI(3,4,5)P3-dependent polarized growth at  
647 the inner tongue. *Cell* **156**, 277-290 (2014).
- 648 6. Brody, B. A., Kinney, H. C., Kloman, A. S. & Gilles, F. H. Sequence of central nervous system myelination in  
649 human infancy. I. An autopsy study of myelination. *J. Neuropathol. Exp. Neurol.* **46**, 283-301 (1987).
- 650 7. Kinney, H. C., Brody, B. A., Kloman, A. S. & Gilles, F. H. Sequence of Central Nervous System Myelination in  
651 Human Infancy. Patterns of Myelination in Autopsied Infants. *J. Neuropathol. Exp. Neurol.* **47**, 217-234  
652 (1988).
- 653 8. Stadelmann, C., Timmler, S., Barrantes-Freer, A. & Simons, M. Myelin in the Central Nervous System: Structure,  
654 Function, and Pathology. *Physiol Rev* **99**, 1381-1431 (2019).
- 655 9. Tomassy, G. S. *et al.* Distinct Profiles of Myelin Distribution. *Science (80-)* **344**, 319-324 (2014).
- 656 10. Call, C. L. & Bergles, D. E. Cortical neurons exhibit diverse myelination patterns that scale between mouse  
657 brain regions and regenerate after demyelination. *Nat. Commun.* **2021** **12**, 1-15 (2021).
- 658 11. Redmond, S. A. *et al.* Somatodendritic Expression of JAM2 Inhibits Oligodendrocyte Myelination. *Neuron* **91**,  
659 824-836 (2016).
- 660 12. Mount, C. W. & Monje, M. Wrapped to Adapt: Experience-Dependent Myelination. *Neuron* **95**, 743-756  
661 (2017).
- 662 13. Nagy, B., Hovhannisyan, A., Barzan, R., Chen, T. J. & Kukley, M. *Different patterns of neuronal activity trigger*  
663 *distinct responses of oligodendrocyte precursor cells in the corpus callosum. PLoS Biology* **15**, (2017).
- 664 14. Gibson, E. M. *et al.* Neuronal activity promotes oligodendrogenesis and adaptive myelination in the  
665 mammalian brain. *Science (80-)* **1252304**, (2014).
- 666 15. Duncan, D. The Importance of Diameter as a Factor in Myelination. *Science (80-)* **79**, 363-363 (1934).
- 667 16. Voyvodic, J. T. Target size regulates calibre and myelination of sympathetic axons. *Nat. 1989* **342** 430-433 (1989).
- 668 17. Fraher, J. & Dockery, P. A strong myelin thickness-axon size correlation emerges in developing nerves despite  
669 independent growth of both parameters. *J. Anat* **193**, 195-201 (1998).
- 670 18. Lee, S. *et al.* A culture system to study oligodendrocyte myelination processes using engineered nanofibers.  
671 *Nat. Methods* **9**, 917-922 (2012).
- 672 19. Stedehouder, J. *et al.* Local axonal morphology guides the topography of interneuron myelination in mouse  
673 and human neocortex. *Elife* **8**, (2019).
- 674 20. Barnea-Goraly, N. *et al.* White Matter Development During Childhood and Adolescence: A Cross-sectional  
675 Diffusion Tensor Imaging Study. *Cereb. Cortex* **15**, (2005).
- 676 21. Goebbels, S. *et al.* A neuronal PI(3,4,5)P3-dependent program of oligodendrocyte precursor recruitment and  
677 myelination. *Nat. Neurosci.* **2016** **20**, 10-15 (2016).
- 678 22. Ryskalin, L. *et al.* mTOR-Dependent Cell Proliferation in the Brain. *Biomed Res. Int.* **2017**, (2017).
- 679 23. Wang, X., Zhang, C., Szábo, G. & Sun, Q. Q. Distribution of CaMKIIα expression in the brain in vivo, studied  
680 by CaMKIIα-GFP mice. *Brain Res.* **1518**, 9 (2013).
- 681 24. Stedehouder, J. *et al.* Fast-spiking Parvalbumin Interneurons are Frequently Myelinated in the Cerebral  
682 Cortex of Mice and Humans. *Cereb. Cortex* **27**, 5001-5013 (2017).
- 683 25. Tomassy, G. S., Dershowitz, L. B. & Arlotta, P. Diversity Matters: A Revised Guide to Myelination. *Trends Cell*  
684 *Biol.* **26**, 135-147 (2016).
- 685 26. Perge, J. A., Niven, J. E., Mugnaini, E., Balasubramanian, V. & Sterling, P. Why Do Axons Differ in Caliber? *J.*  
686 *Neurosci.* **32**, 626-638 (2012).
- 687 27. Friedman, N. P. & Robbins, T. W. The role of prefrontal cortex in cognitive control and executive function.  
688 *Neuropsychopharmacol.* **2021** **471**, 72-89 (2021).

690 28. Kolk, S. M. & Rakic, P. Development of prefrontal cortex. *Neuropsychopharmacol.* 2021 **47**, 41-57 (2021).

691 29. Flechsig, P. Developmental (myelogenetic) localisation of the cerebral cortex in the human subject. *Lancet*  
692 (*London, England*) **1898**, 1027-1030 (1900).

693 30. Fuster, J. M. Frontal lobe and cognitive development. *J. Neurocytol.* 2002 **31**, 373-385 (2002).

694 31. Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through  
695 experience-dependent oligodendrogenesis in the adult somatosensory cortex. *Nat. Neurosci.* 2018 **21**,  
696 696-706 (2018).

697 32. Hill, R. A., Li, A. M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related degeneration in the live  
698 mammalian brain. *Nat. Neurosci.* **21**, 683-695 (2018).

699 33. Freeman, S. A. et al. Acceleration of conduction velocity linked to clustering of nodal components precedes  
700 myelination. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E321-E328 (2015).

701 34. Chéreau, R., Saraceno, G. E., Angibaud, J., Cattaert, D. & Nägerl, U. V. Superresolution imaging reveals  
702 activity-dependent plasticity of axon morphology linked to changes in action potential conduction velocity.  
703 *Proc. Natl. Acad. Sci. U. S. A.* **114**, 1401-1406 (2017).

704 35. Hines, J. H., Ravanelli, A. M., Schwindt, R., Scott, E. K. & Appel, B. Neuronal activity biases axon selection for  
705 myelination in vivo. *Nat. Neurosci.* **18**, 683-689 (2015).

706 36. Stedehouder, J., Brizee, D., Shpak, G. & Kushner, S. A. Activity-Dependent Myelination of Parvalbumin  
707 Interneurons Mediated by Axonal Morphological Plasticity. *J. Neurosci.* **38**, 3631-3642 (2018).

708 37. Suminaite, D., Lyons, D. A. & Livesey, M. R. Myelinated axon physiology and regulation of neural circuit  
709 function. *Glia* **67**, 2050 (2019).

710 38. Zuchero, J. B. & Barres, B. A. Intrinsic and extrinsic control of oligodendrocyte development Origin and OPC  
711 specification. (2013). doi:10.1016/j.conb.2013.06.005

712 39. Almeida, R. G. The rules of attraction in central nervous system myelination. *Front. Cell. Neurosci.* **12**, 367  
713 (2018).

714 40. Bechler, M. E., Byrne, L. & Ffrench-Constant, C. CNS Myelin Sheath Lengths Are an Intrinsic Property of  
715 Oligodendrocytes. *Curr. Biol.* **25**, 2411-2416 (2015).

716 41. Lei, Z. & Chiu, S. Y. Computer model for action potential propagation through branch point in myelinated  
717 nerves. *J. Neurophysiol.* **85**, 197-210 (2001).

718 42. Kole, M. H. P. First node of ranvier facilitates high-frequency burst encoding. *Neuron* **71**, 671-682 (2011).

719